Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Puchades, Maja | Sogn, Carl Johan | Maehlen, Jan | Bergersen, Linda H.; ; ; | Gundersen, Vidar;
Affiliations: Glio- and Neurotransmitter Group, Centre for Molecular Biology and Neuroscience and Institute for Basic Medical Sciences, University of Oslo, Oslo, Norway | Department of Pathology, Oslo University Hospital-Ullevål. Oslo, Norway | The Brain and Muscle Energy Group, Centre for Molecular Biology and Neuroscience and Institute for Basic Medical Sciences, University of Oslo, Oslo, Norway | Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark | Center for Healthy Aging, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark | Department of Neurology, Oslo University Hospital, Norway | Department of Oral Biology, University of Oslo, Norway
Note: [] Correspondence to: Vidar Gundersen, Department of Anatomy and Centre for Molecular Biology and Neuroscience, University of Oslo, P.O. Box 1105 Blindern, N-0317 Oslo, Norway. Tel.: +47 22851496; E-mails: [email protected] (Vidar Gundersen); [email protected] (Maja Puchades); [email protected] (Carl Johan Sogn); [email protected] (Jan Maehlen); [email protected] (Linda H. Bergersen).
Abstract: Background: Metabolic impairment contributes to development of Parkinson's disease (PD). Mitochondrial dysfunction is involved in degeneration of nigral dopamine neurons. Also, in PD there are alterations in glucose metabolism in nigro-striatal pathways, and increased cerebral lactate levels have been found. Objectives: We raise the question of whether changes in the amount transporters of energy substrates are involved in the pathogenesis of PD. Methods: We have used confocal immunofluorescence and immunogold postembedding electron microscopic techniques to study whether there are altered levels of the transporters for monocarboxylates (MCT1 and MCT2) and glucose (GLUT1) in the MPTP mouse model of PD. Results: We found that MCT1 and GLUT1 were densely located in blood vessel endothelium, while MCT2 was present in perivascular astrocytic end feet processes in the substantia nigra and the striatum of control mice. We found that the localisation and densities of MCTs and GLUT1 were unaltered in the PD model. Discussion: This is the first study reporting on the distribution of metabolic transporters in PD. Our results suggest that, although there are metabolic impairments in PD, the levels of MCT1, MCT2 and GLUT1 is not changed following dopaminergic neurodegeneration. This is in contrast to findings in other neurodegenerative disease, such as mesial temporal lobe epilepsy, where there are large alterations in MCT levels.
Keywords: Parkinson's disease, monocarboxylic acid transporters, energy metabolism, neurodegenerative disease, brain
DOI: 10.3233/JPD-130190
Journal: Journal of Parkinson's Disease, vol. 3, no. 3, pp. 371-385, 2013
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]